GlaxoSmithKline is looking for opportunities in Infectious diseases
Collaboration with others in industry, academia, government and non-governmental organisations and healthcare in general is fundamental to GSK's strategic priorities of growing a diversified, global business and delivering more products of value.
Their Worldwide Business Development group is a global team of scientific, transaction, and alliance management experts building diverse collaborations relating to compounds (early stage discovery programs through to marketed products) and technologies. If you prefer to retain the independence to develop alliance compounds through to proof of concept, their Options based collaborative model offers you the flexibility for you to do so. They have an industry leading record in establishing and maintaining collaborations with scientists and organizations in both industry and academia and are experts at building progressive relationships that are strong and mutually beneficial.
Priority areas of science
They are strongly committed to research collaborations with academic groups to advance scientific understanding relevant to their key areas of focus:
- Metabolic pathways
- Infectious diseases
Specific topics of interest currently for academic collaboration are outlined below.
- New approaches for treating viral (including HCV, HIV, RSV, HPV, HBV) and bacterial infections
- Rapid diagnostic systems for viral and bacterial infections
- Generation of epidemiology/surveillance data, particularly in emerging markets
- Validated biomarkers and surrogates for cardiovascular risk factors in HIV showing links between changes in biomarkers/surrogates and clinical events
- Validated cardiovascular risk calculator for HIV patients
- Enhanced quality and more efficient short-term surrogate endpoints for long-term clinical events in HIV and HCV
- Validated quality of life tools for HIV